Reliance Life Sciences Private Limited

October 24, 2025

Facilities/Instruments	Amount (₹ crore)	Rating[1]	Rating Action
Long-term bank facilities	1,375.05	CARE AAA; Stable	Reaffirmed
Long-term / Short-term bank facilities	770.00	CARE AAA; Stable / CARE A1+	Reaffirmed
Short-term bank facilities	54.95	CARE A1+	Reaffirmed
Non-convertible debentures	500.00	CARE AAA; Stable	Reaffirmed

Details of instruments/facilities in Annexure-1.

Rationale and key rating drivers

Ratings assigned to bank facilities and instrument of Reliance Life Sciences Private Limited (RLSPL) continue to draw significant comfort from its parentage, with 100% ownership of the company being held by the resourceful Reliance group promoter companies (led by Mukesh Ambani), which has also infused significant unsecured loans in the company. Ratings are further underpinned by the niche nature of its therapeutic products in the life sciences sector, strong market position of its key products in the biopharmaceutical segment, integrated in-house infrastructure and capabilities in research and development (R&D), process development, clinical development, manufacturing and marketing, accreditations from national and global agencies and patents held by RLSPL, comfortable financial risk profile and its strong liquidity.

Rating strengths are partially offset by prevalent regulatory risks in both, domestic and international markets, and inherently long gestation life cycle of the products dealt by RLSPL, and risks associated with its large-size capex under subsidiary, which is nearing full completion.

Rating sensitivities: Factors likely to lead to rating actions

Positive factors: Not applicable

Negative factors

- Changes in the Reliance (Mukesh Ambani) group's strategy, impacting financial flexibility of the company.
- Adverse impact of regulatory changes on operational performance of the company.
- Deterioration in net debt/profit before interest, lease rentals, depreciation, and taxation (PBILDT) beyond 2.5x on a sustained basis.

Analytical approach: Consolidated

CARE Ratings Limited (CareEdge Ratings) has taken a consolidated analytical approach owing to strong financial and operational linkages of RLSPL with its subsidiary, Reliance Life Sciences Nashik Private Limited (RLSNPL), and common management. Companies consolidated in RLSPL are listed under Annexure-6.
For RLSPL's ratings, CareEdge Ratings has also factored in comfort from the resourcefulness, financial strength, and flexibility of the Reliance Group promoter companies, led by Mukesh Ambani, with Reliance Industries Limited (RIL) being the group's flagship company. RLSPL is one of the key ventures of the Reliance Group in the pharmaceutical business segment, where, the group has supported its operations and growth plans through infusion of unsecured loans and preference shares. The group has also extended its common corporate brand name "Reliance" to RLSPL.

Outlook: Stable

CareEdge Ratings believes strong market position of the company shall benefit its business risk profile. Being strategically important to the Reliance group, RLSPL shall continue to receive financial and managerial support from the group especially in implementation and stabilisation phase of its capex, ensuring comfortable financial risk profile and liquidity position.

[1]Complete definition of ratings assigned are available at www.careratings.com and other CARE Ratings Limited's publications.

Detailed description of key rating drivers:

Key strengths

Strong promoter group (Reliance, Mukesh Ambani Group) with demonstrated support, which is likely to sustain

RLSPL is an initiative of the Mukesh Ambani-led Reliance group of companies. The Reliance Group is the largest private sector enterprise in India, with presence across varied businesses in the energy and materials value-chain, and ventures in consumer-facing businesses. The flagship company, RIL (rated 'CARE AAA; Stable/ CARE A1+'), is a Fortune Global 500 company. Being part of the Reliance group, RLSPL, while independent in its day-to-day operations, gets need-based support from group companies. In the past, promoters/group companies have infused funds in the form of long-term unsecured loans and preference shares in RLSPL.

Dominant position in two key products; deep product pipeline

RLSPL is one of the major manufacturers of plasma proteins in South Asia. The company is an integrated manufacturer of Human Albumin and Immunoglobulin in South Asia and holds a strong market position in these two product categories in the domestic market. The company has moderately diversified product portfolio with top seven products contributing ~60%-70% of the total operating income (TOI). The company has diversified geographical presence, with operations spanning over 65 countries. Exports formed ~52% of the TOI in FY25 (~46% in FY24).

There are significant entry barriers for integrated manufacturers in plasma proteins because of limited sources of plasma and plasma intermediates and complexity in manufacturing and testing these products. RLSPL has developed the entire supply chain and technology of manufacturing and testing these products in the last decade. Plasma proteins are largely supplied directly by RLSPL, under its own brand, to hospitals in India and other foreign markets, whereas in the UK market, it is through third parties.

RLSPL has launched five of the world's first biosimilars and has large number of biosimilars in the Indian market, and several are under development. Several biopharmaceutical and pharmaceutical products under development for domestic and international markets are expected to translate into significant revenue potential for the company in the future.

Integrated in-house infrastructure and capabilities in R&D, process development, clinical trial, manufacturing and marketing

The flagship facility is the Dhirubhai Ambani Life Sciences Centre (DALC) in Navi Mumbai, spread over 20 acres. RLSPL operates state-of-the-art facilities in the life sciences domain, with DALC being among the most diverse and integrated life sciences centres in the world. The company is capable of undertaking R&D in a wide range of fields, and its manufacturing units are well-integrated with facilities for repository, laboratory research, pre-clinical research, and clinical trials. The company's in-house R&D facility is recognised by the Department of Scientific and Industrial Research (DSIR). The company's R&D expenditure ranges between ₹100-₹150 crore annually. RLSPL operates facilities for manufacturing plasma proteins, biosimilars and pharmaceuticals products conforming to Indian FDA, WHO-GMP, EMEA, and the US Food and Drug Administration (USFDA) standards. RLSPL is one of the few centres in the world offering a specialised range of tests in molecular medicine and molecular genetics. Currently, the capacity at DALC is largely utilised. The company is setting up another plant at Nashik under its subsidiary, RLSNPL, which has a land parcel of ~160 acres. Under phase-1 expansion, the capacity being set up is ~2x of current capacity in RLSPL which is nearing completion and post stabilisation of the said plant, the company is likely to embark on a similar expansion under Phase-2.

High level quality standards with accreditations from national and global agencies

The business of developing and producing biopharmaceuticals, pharmaceuticals, and other high-end products entail high level of quality standards. RLSPL's biopharmaceutical and pharmaceutical product manufacturing plants are approved by European regulatory authorities and health authorities of countries, including Brazil, Columbia, Egypt, and Turkey. RLSPL enjoys accreditations from accrediting organisations, such as the College of American Pathologists (CAP), the National Accreditation Board for Testing and Calibration Laboratories (NABL), Clinical Laboratory Improvement Amendments (CLIA), the American Association of Blood Banks (AABB), accreditations for cord blood repository, and the Organisation of Economic Cooperation and Development-Good Laboratory Practices (OECD-GLP). The DALC facility for manufacturing pharmaceutical products has also been approved by the USFDA.

Satisfactory operating performance in FY25 albeit moderation in H1FY26, comfortable financial profile

RLSPL's TOI improved by 16% y-o-y in FY25 to ₹2,565 crore led by increase in revenue mainly from biopharmaceutical segment and pharmaceutical segment. Revenue of biopharmaceutical segment, which includes plasma proteins and biosimilars, grew 19% y-o-y and remained key contributor, accounting for ~ 87% of TOI in FY25 (compared to ~85% in FY24), while revenue of pharmaceutical segment, contributing 11% to TOI (FY24: 9%), grew by 37% y-o-y. However, decline in diagnostics segment revenue restricted overall growth in revenue in FY25. Despite healthy increase in revenue, PBILDT margin declined to 30.43% in FY25 from 36.30% in FY24 considering increase in raw material cost, other operating cost, and decline in contribution from higher margin diagnostic segment. PBILDT margin further moderated to 19.5% in H1FY26, on the back of elevated cost of plasma proteins on the back of its higher demand from the industry and lower availability. The company initiated bulk procurement of the raw materials in H1FY26, ensuring continued availability, which is expected to ensure strong recovery in PBILDT margin H2FY26. CareEdge Ratings expects TOI to witness healthy growth in FY26 supported by continued robust performance in the biopharmaceutical segment and scale up of operations of its subsidiary, RLSNPL, which partially commenced operations in March 2024. Despite margin pressure in H1FY26, profitability is projected to remain healthy for the full fiscal year, supported by expectations of recovery in profitability in H2FY26 from measures undertaken towards availability of its raw materials.

RLSPL has comfortable financial risk profile underpinned by healthy profitability, low leverage, strong debt coverage indicators and free liquidity of ~ ₹363 crore as on March 31, 2025.

Stable outlook for Indian pharmaceutical industry and favourable growth prospects in biopharmaceuticals segment

Indian pharmaceutical industry size is estimated at US$59.8 billion in FY25 and is estimated to reach at ~US$92 billion by FY30 with expected CAGR of ~9%. The Indian pharmaceutical sector commands a significant global presence, particularly in the generic segment, where it ranks as the third largest by volume and 13th by value. Export momentum is expected to remain robust, with pharmaceutical exports at US$30.3 billion in FY25 to grow to US$35.8 billion by FY27. The United States of America (US) continued to be the prime export destination for the industry, contributing 35% of total outbound shipments in FY25. North America as a region is expected to account for 54% of exports in FY25, rising to 56% by FY27. India's competitive positioning in the US generics market is reinforced by its consistent share of USFDA abbreviated new drug application (ANDA) approvals, which ranged between 40–48% in recent years. RLSPL has negligible sales to the US, and hence, is not expected to be impacted by recent imposition of tariffs. The foreseeable future presents a promising outlook for the industry in exports market, characterised by increasing demand within both regulated and emerging pharmaceutical markets. The global patent cliff, with US$125 billion worth of drug molecules set to lose exclusivity between 2024 and 2026, presents a significant opportunity for Indian manufacturers.

India is the third-largest biotechnology destination in Asia-Pacific and one of the top 12 biotechnology locations worldwide. India's Biotechnology sector is categorised into Biopharmaceuticals, Bioagriculture, Bio IT, and Bio Services, of which Biopharmaceuticals is the largest segment. The rise in domestic demand is fuelled by initiatives such as Aatmanirbhar Bharat and Make in India, while overseas demand for Indian vaccines and biopharmaceuticals is due to the globally competitive efficacy of Indian products. To contain healthcare costs, companies are leveraging generics and biosimilars, and India has poised itself as a hub to deliver affordable access to innovative and inclusive healthcare solutions. With its expertise, infrastructure, and investments, India is poised to command a decent share within the next decade.

Liquidity: Strong

RLSPL's liquidity is marked by strong annual cash accruals of over ₹550 crore in FY25 and ~₹110 crore in H1FY26 and free cash balances and liquid investments in the form of mutual funds of ~₹277 crore as on September 30, 2025, against debt repayment obligation of ~₹299 crore in FY26 and ~₹362 crore in FY27. The average utilisation of fund-based limits of the company stood low at ~39% for 12 months ended August 2025 which provides an additional liquidity cushion.

In FY24, the company availed external debt of ₹500 crore and retired high-cost promoter debt to that extent. In FY25, the company raised ₹500 crore through non-convertible debenture (NCD) for its working capital requirement and funding capex commitment in subsidiary. The capex under subsidiary is expected to be completed by FY26-end. With overall gearing of 0.67x as on March 31, 2025, RLSPL has sufficient gearing headroom, to raise additional debt for its capex although company has no plans for availment of further long-term debt in the medium term. Being part of the Reliance group, the company enjoys superior financial flexibility.

Key weaknesses

Regulatory and legal risks with respect to acceptability and approval of products with small target market (metros and mini-metros) due to highly priced niche products

All products sold by RLSPL are manufactured in-house and are high-end niche products. In general, these products take longer to develop, and furthermore, require additional time before they can be marketed, as they must pass through rigorous regulatory examination and clinical trials. Even after these products have been fully developed, they have to undergo rigorous testing processes by regulatory authorities in countries, with each country having its own set of rules and regulations. Some products take 7-8 years to develop. The kind of drugs in which RLSPL specialises are not widely used in India, as they are quite expensive. Hence, the market, although growing, is still at a nascent stage and is expected to take some time to mature.

Risks associated with implementation and stabilisation of large-size greenfield project and expansion capital expenditure

RLSPL has taken up a greenfield project of building a research and manufacturing facility at Dindori, Nashik, such as the existing one at DALC through its wholly owned subsidiary, RLSNPL. The facility shall have verticals such as Plasma Proteins, Biosimilars, Pharmaceuticals, Clinical Research, Regenerative Medicine, Cord Blood Repository and Diagnostics with installed capacity of ~2x of DALC facility. The total cost of this project is estimated at ~₹2,200 crore. Till date, the company has spent ~₹2,000 crore towards the project through internal accruals, unsecured loans from promoter group entities, available liquidity and issuance of NCD. The pharmaceutical segment largely commissioned commercial operations in March 2024, while plasma proteins segment has commenced operations in FY25. Balance plants are expected to commence commercial operations by March 31, 2026, with completion of the entire project. RLSNPL registered revenue of ₹172 crore in FY25 and ₹264 crore in H1FY26 while PBILDT margin stood at 0.4% and 8.5% respectively.

Post completion and stabilisation of phase-1, the company plans to embark upon phase-2 expansion at Nashik at similar project cost of ~₹2,200 crore. This apart, RLSPL, at a standalone level, has also envisaged a capex of ~₹125 crore in FY26 towards ongoing expansion of its biosimilar facility, pilot plant for Gene therapy, development of human and animal vaccines and increasing focus on plasma proteins and development of Peptide drugs. Completion of the greenfield capex in RLSNPL and expansion capex in RLSPL in a timely manner and stabilisation and revenue generation will be a key monitorable.

Applicable criteria

Consolidation
Definition of Default
Factoring Linkages Parent Sub JV Group
Liquidity Analysis of Non-financial sector entities
Rating Outlook and Rating Watch
Manufacturing Companies
Pharmaceuticals
Financial Ratios – Non financial Sector
Short Term Instruments

About the company and industry

Industry classification

Macroeconomic indicator	Sector	Industry	Basic industry
Healthcare	Healthcare	Pharmaceuticals & biotechnology	Biotechnology

RLSPL is a diversified and integrated biotechnology initiative of the Mukesh Ambani-led Reliance Group. RLSPL was incorporated in 2001 to develop business opportunities in the medical, plant and industrial biotechnology sectors. RLSPL is primarily involved in biopharmaceuticals (plasma proteins, bio-similars, and novel proteins), pharmaceuticals (active pharmaceutical intermediates [APIs], formulations, and drug discovery), clinical research services (Pre-clinical animal studies, bio availability, and bio equivalence studies, Phase 1 to Phase 4 studies, and others), regenerative medicine (stem cell therapies, and tissue engineered products, among others), molecular medicine (DNA-based diagnostics, molecular genetics, predictive diagnostics), novel therapeutics (RNA molecules), R&D activities, and industrial biotechnology (biopolymers, bio-chemicals).

RLSPL's main facility is at DALC in Navi Mumbai. Clinical research services are also provided out of DALC. The company is also undertaking a greenfield expansion through its wholly owned subsidiary, RLSNPL, to build a facility similar to DALC at Dindori, Nashik which is expected to be fully completed by March 31, 2026.

Brief Financials (₹ crore)-Consolidated	FY24 (A)	FY25 (A)	H1FY26 (UA)
Total operating income	2,205.18	2,565.10	1,282.51
PBILDT	800.53	780.68	249.63
PAT	419.88	437.63	23.47
Overall gearing (times)	0.56	0.67	0.73
Interest coverage (times)	8.42	6.74	3.36

A: Audited UA: Unaudited; Note: these are latest available financial results
Financials are reclassified per CareEdge Ratings' standards.

Status of non-cooperation with previous CRA: Not applicable

Any other information: Not applicable

Rating history for last three years: Annexure-2

Detailed explanation of covenants of rated instrument / facility: Annexure-3

Complexity level of instruments rated: Annexure-4

Lender details: Annexure-5

Annexure-1: Details of instruments/facilities

Name of the Instrument	ISIN	Date of Issuance (DD-MM-YYYY)	Coupon Rate (%)	Maturity Date (DD-MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned and Rating Outlook
Debentures-Non Convertible Debentures	INE11LM07015	06-Nov-2024	7.7954	13-Nov-2025	100.00	CARE AAA; Stable
Debentures-Non Convertible Debentures	INE11LM07023	06-Nov-2024	7.7954	08-May-2026	200.00	CARE AAA; Stable
Debentures-Non Convertible Debentures	INE11LM07031	06-Nov-2024	7.7954	05-Nov-2027	200.00	CARE AAA; Stable
Fund-based - LT-Term Loan		-	-	31-Dec-2028	1,350.00	CARE AAA; Stable
Fund-based-Long Term		-	-	-	25.05	CARE AAA; Stable
Fund-based/Non-fund-based-LT/ST		-	-	-	770.00	CARE AAA; Stable / CARE A1+
Non-fund-based-Short Term		-	-	-	54.95	CARE A1+

Annexure-2: Rating history for last three years

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating History			
		Type	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2025-2026	Date(s) and Rating(s) assigned in 2024-2025	Date(s) and Rating(s) assigned in 2023-2024	Date(s) and Rating(s) assigned in 2022-2023
1	Fund-based-Long Term	LT	25.05	CARE AAA; Stable	-	1)CARE AAA; Stable (21-Oct-24)	1)CARE AAA; Stable (05-Jan-24)	1)CARE AAA; Stable (21-Feb-23)
2	Non-fund-based-Short Term	ST	54.95	CARE A1+	-	1)CARE A1+ (21-Oct-24)	1)CARE A1+ (05-Jan-24)	1)CARE A1+ (21-Feb-23)
3	Fund-based - LT-Term Loan	LT	1350.00	CARE AAA; Stable	-	1)CARE AAA; Stable (21-Oct-24)	1)CARE AAA; Stable (05-Jan-24)	1)CARE AAA; Stable (21-Feb-23)
4	Debentures-Non Convertible Debentures	LT	500.00	CARE AAA; Stable	-	1)CARE AAA; Stable (25-Oct-24)	-	-
5	Fund-based/Non-fund-based-LT/ST	LT/ST	770.00	CARE AAA; Stable / CARE A1+	-	1)CARE AAA; Stable / CARE A1+ (21-Oct-24)	-	-

LT: Long term; ST: Short term; LT/ST: Long term/Short term

Annexure-3: Detailed explanation of covenants of rated instruments/facilities: Not applicable

Annexure-4: Complexity level of instruments rated

Sr. No.	Name of the Instrument	Complexity Level
1	Debentures-Non Convertible Debentures	Simple
2	Fund-based - LT-Term Loan	Simple
3	Fund-based-Long Term	Simple
4	Fund-based/Non-fund-based-LT/ST	Simple
5	Non-fund-based-Short Term	Simple

Annexure-5: Lender details

To view lender-wise details of bank facilities please click here

Annexure-6: List of entities consolidated

Sr No	Name of the entity	Extent of consolidation	Rationale for consolidation
1	Reliance Life Sciences Nashik Private Limited	Full	Subsidiary

Note on complexity levels of rated instruments: CareEdge Ratings has classified instruments rated by it based on complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for clarifications.

Contact us

Media Contact	Analytical Contacts
Name: Mradul Mishra Director **CARE Ratings Limited** Phone: +91-22-6754 3596 E-mail: mradul.mishra@careedge.in	Name: Hardik Shah Director **CARE Ratings Limited** Phone: +91-22-6754 3591 E-mail: hardik.shah@careedge.in
Relationship Contact Name: Saikat Roy Senior Director **CARE Ratings Limited** Phone: +91-22-6754 3404 E-mail: saikat.roy@careedge.in	Name: Rabin Bihani Associate Director **CARE Ratings Limited** Phone: +91-22-6754 3592 E-mail: rabin.bihani@careedge.in Komal Vinit Soni Assistant Director **CARE Ratings Limited** E-mail: komal.israni@careedge.in

About us:
Established in 1993, CareEdge Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the Reserve Bank of India. With an equitable position in the Indian capital market, CareEdge Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CareEdge Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CareEdge Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit. For more information: www.careratings.com

For detailed Rating Report and subscription information,
please visit www.careratings.com